(T 9) Time course of rimegepant efficacy for the prevention of episodic migraine in a phase 4 trial enrolling participants with prior inadequate responses to 2 to 4 categories of non-migraine-specific oral preventive medications

Presenting Author(s)

MB

Magdalena Boczarska-Jedynak, n/a

Institute of Health Dr. Boczarska-Jedynak, Oświęcim, Poland, Poland
LR

Luz M. Ramirez, n/a

Pfizer Inc., Princeton, NJ, USA
Princeton, New Jersey, United States
AA

Ayse Neslihan Aslan, n/a

Pfizer Inc., Istanbul, Turkey, Turkey
SR

Sara Anne Ramaker, n/a

Pfizer Inc., Collegeville, PA, USA, United States
SM

Shannin McCollum, n/a

Pfizer Inc., Groton, CT, USA, United States
AT

Alexandra Thiry, n/a

Pfizer Inc., Groton, CT, USA
Groton, Connecticut, United States
Robert J. Fountaine, n/a

Global Clinical Lead - CGRP Migraine Franchise
Pfizer Inc., New York, NY, USA
Groton, Connecticut, United States
HS

Harpreet Seehra, n/a

Pfizer R&D UK Ltd., Tadworth, Surrey, UK, United Kingdom